Latest IMS Health Stories
PARSIPPANY, N.J., March 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone gel 10mg/0.5g. Actavis' ANDA product is a generic version of Endo Pharmaceuticals' Fortesta(®), which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Endo and...
QUEBEC CITY, Feb. 27, 2013 /PRNewswire/ - Atrium Innovations Inc. (TSX: ATB), a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today announces that it has entered into a joint venture contract with Fosun Industrial, incorporated in Hong Kong, wholly owned of Shanghai-based Fosun Pharma for the purposes of distributing Atrium brands in China. According to IMS Health...
PITTSBURGH, Feb. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. This product is the generic version of Lupin Atlantis Holdings, S.A.'s Antara(®) Capsules, which are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and to...
PARSIPPANY, N.J., Feb. 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone(®). Actavis intends to begin shipping the product immediately. Suboxone(®) is indicated for maintenance treatment...
MT. OLIVE, N.J., Feb. 19, 2013 /PRNewswire/ -- The Annual Pinsonault Managed Markets Summit begins Tuesday, February 26 at the InterContinental in Miami, FL. Among highlights, Captain Mark Kelly, Commander of the space shuttle Endeavour and retired U.S. Navy captain, will be one of the keynote presenters to take the stage during the three-day event. Kelly's wife, U.S. Congresswoman Gabby Giffords is also scheduled to make a guest appearance. Rounding out the keynote line-up,...
TEANECK, N.J., Feb. 13, 2013 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it has been positioned as a Leader in the IDC Health Insights "IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment" (document number HI239221, dated February 2013). The IDC MarketScape report evaluated leading drug safety services (DSS) providers in the life science industry. The evaluation was based on a comprehensive framework, and assessed services providers...
PORTLAND, Maine, Feb. 11, 2013 /PRNewswire/ -- Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has launched generic veterinary Cefpodoxime Proxetil tablets. Putney's veterinary Cefpodoxime Proxetil is the first and only generic approved by the FDA's Center for Veterinary Medicine (CVM) as equivalent to Simplicef®. Putney's generic Cefpodoxime Proxetil is FDA CVM approved to treat certain skin...
BOSTON, Jan. 23, 2013 /PRNewswire/ -- TPG has signed a definitive agreement to acquire Eze Castle Software, a premier provider of global order management and related investment technologies, and RealTick, a leading multi?broker, cross?asset electronic execution platform, from ConvergEx Group. This all cash transaction is expected to close in Q1 or Q2 of 2013. Financial terms were not disclosed. The newly formed company will be called Eze Software Group. Following the close of the...
MUMBAI and BALTIMORE, January 22, 2013 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Watson Laboratories, Inc.'s Lutera(R) 28 Tablets. Lupin's Levonorgestrel and Ethinyl Estradiol Tablets are a...
SAN FRANCISCO, Jan. 7, 2013 /PRNewswire/ -- Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through mergers and acquisitions (M&A). But big pharma's attempts to make deals will be challenged by its diminished resources and fiercer competition for attractive assets from rapidly growing big biotech and specialty pharma companies. These and other findings were released today by Ernst & Young in the report...
